Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma
NCT05432791Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of olaparib, temozolomide in uterine leiomyosarcoma (uLMS), sponsored by National Cancer Institute. Started Mar 2023; status: active, not recruiting.
02
Drugs
olaparibtemozolomide
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT05432791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432791.